LitAlert ~~

    • How should we address the inevitable harms from non-negligent variant reclassification in predictive genetic testing?
    • Rashkin M, Kingham K, Lara-Otero , Mckenna M, Villiers J, Worthington MM, Prince A.
    • J Genet Couns. 2022 Oct 19. doi: 10.1002/jgc4.1638. Epub ahead of print.
    • Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
    • Cheng A, Rao Q, Liu Y, Huo C, Lin Z, Lu H.
    • Gynecol Oncol. 2022 Oct 18:S0090-8258(22)01888-1. doi: 10.1016/j.ygyno.2022.10.011. Epub ahead of print.
    • Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
    • Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP.
    • J Clin Oncol. 2022 Oct 18:JCO2102947. doi: 10.1200/JCO.21.02947. Epub ahead of print.

    Identifier: NCT02893917: Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer. ( . Accessed 2022 Oct 19.)

    • Dr. Karlan on Current Research Evaluating PARP Inhibitor Combination Therapy in Ovarian Cancer.
    • Karlan BY.
    • OncLive. OncLive TV. 2022 Oct 18.
    • Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges.
    • Zhang X, Huo X, Guo H, Xue L.
    • Front Pharmacol. 2022 Oct 3;13:965244. doi: 10.3389/fphar.2022.965244.